Sign in
Taking people in United StatesEarly phase 1

Lactobacillus crispatus bladder instillation for urinary infections in people with spinal cord injury

Tests Lactobacillus crispatus bladder washes for safety in adults with spinal cord injury bladder problems.

Key facts

Who runs it
Medstar Health Research Institute
Where
Washington D.C., United StatesSee the site
Trial code
Registry title
Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation
Status
Recruiting
Phase
Early phase 1
People taking part
40 people, planned
Started
9 Sept 2025
Expected to end
30 Mar 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Lactobacillus Crispatus
  • Saline bladder wash
Record updated
30 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a spinal cord injury and bladder problems caused by nerve damage, who empty their bladder with a catheter several times a day. It tests putting Lactobacillus crispatus bacteria into the bladder, compared with salt water (saline).

Age
18 years and older
Sex
All sexes
Disease stage
Spinal cord injury for at least 6 months, with bladder problems caused by nerve damage (NLUTD). People must live in the community, not in a care facility.
Earlier treatment
People must use intermittent catheterization (passing a tube into the bladder from time to time) to empty the bladder. People cannot join if they used antibiotics by mouth or IV in the past 2 weeks.

Main reasons for not taking part

  • Taking antibiotics regularly to prevent infection, or putting germ-killing medicine into the bladder to prevent UTI
  • Use of oral or IV antibiotics in the past 2 weeks
  • Pregnancy
  • Known urinary or genital problems other than the nerve-related bladder problem
  • Mental health conditions that affect following instructions, or being in another study that could affect the results

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • SCI with at least 6-month duration
  • NLUTD
  • Utilizing intermittent catheterization for bladder management
  • Community dwelling

Who cannot take part

  • Psychological or psychiatric conditions influencing the ability to follow instructions
  • Use of prophylactic antibiotics
  • Instillation of intravesical antimicrobials to prevent UTI
  • Use of oral or IV antibiotics in the past 2 weeks
  • Pregnancy
  • Known genitourinary pathology beyond NLUTD
  • Participation in another study that could confound results of the proposed study

This trial is currently available in United States.

  • MedStar National Rehabilitation HospitalWashington D.C., United StatesContact: Emily Leonard, PhDTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to determine whether Lactobacillus crispatus strains isolated from the lower urinary tracts of adult women can be used as an antibiotic-sparing treatment for urinary symptoms and urinary tract infection (UTI) among adults with neurogenic lower urinary tract dysfunction (NLUTD). The main question[s] it aims to answer are:

Read full original descriptionShow less

1. To identify soluble bactericidal compounds produced by urinary isolates of L. crispatus that kill uropathogenic E. coli (UPEC). 2. To determine if intravesical instillation of L. crispatus is safe and well tolerated in adults with NLUTD due to SCI who use intermittent catheterization (IC).

If there is a comparison group: Researchers will compare L. Crispatus to standard care saline to see if there is a difference in urinary symptoms and urinary microbiome.

Participants will be asked to complete daily symptom surveys, complete 2 bladder instillations, and collect, freeze, and return 14 urine samples.

The 2 groups in the trial

  • Lactobacillus Crispatus bladder washTreatment being tested

    L. crispatus mixed with normal saline and instilled into the bladder will be used for intervention group. Subjects in the intervention group will be instructed to mix the contents of the applicator (by depressing the plunger, which extrudes the L. crispatus powder) into 45 cc of sterile 0.9% saline. After mixing, subjects will draw up the 45cc liquid L. crispatus mixture into a 60cc catheter tip syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Subjects will receive 2 doses (each in separate applicators) of L.crispatus and will repeat this process the following night 24 hours (+/- 2 hours) apart.

    Treatment: Lactobacillus Crispatus

  • Saline Bladder WashOther group

    Subjects will draw up the 45cc sterile saline into a 60cc catheter tip syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Subjects will receive 2 doses of saline and will repeat this process the following night 24 hours (+/- 2 hours) apart.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation
Plain-language title
Lactobacillus crispatus bladder instillation for urinary infections in people with spinal cord injuryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
30 December 2025